Skip to main content
SpringerLink
Log in

Transdermal Oxybutynin

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ Oxybutynin inhibits contraction of the detrusor muscle in the overactive bladder by binding to muscarinic M3 receptors and blocking acetylcholinergic activation.

  • ▴ The transdermal oxybutynin system, applied twice weekly, delivers continuous oxybutynin over a 96-hour patch wear period. The transdermal route of administration avoids the extensive first-pass metabolism of oxybutynin to its active metabolite, N- desethyloxybutynin.

  • ▴ In two well designed trials in patients with overactive bladder, transdermal oxybutynin 3.9 mg/day decreased the number of incontinence episodes and increased average voided volume to a significantly greater extent than placebo. Urinary frequency was improved to a significantly greater extent with transdermal oxybutynin than with placebo in one trial but not the other.

  • ▴ There was no significant difference between transdermal oxybutynin and extended-release oral tolterodine for any of these endpoints.

  • ▴ Health-related quality-of-life improvements with transdermal oxybutynin were shown in patients with overactive bladder in the open-label MATRIX trial, as demonstrated by significant improvements in all domains of the King’s Health Questionnaire.

  • ▴ Transdermal oxybutynin is generally well tolerated in patients with overactive bladder. The majority of patients who discontinued transdermal oxybutynin treatment in two pivotal trials did so because of application-site reactions. However, none discontinued treatment because of dry mouth.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. International Continence Society. ICS factsheet 2: overactive bladder [online]. Available from URL: http://www.icsoffice.org/ASPNET_Membership/Membership/Documents/Documents.aspx?FolderID=30 [Accessed 2009 Feb 25]

  2. Diokno AC. Medical management of urinary incontinence. Gastroenterology 2004; 126(1): S77–81

    Article  PubMed  Google Scholar 

  3. AHCPR. Managing acute and chronic urinary incontinence. Am Fam Physician 1996 Oct; 54: 1661–72

    Google Scholar 

  4. UCB. The first European transdermal oxybutynin treatment for overactive bladder, Kentera® [media release]. 2005

  5. Starkman JS, Dmochowski RR. Management of overactive bladder with transdermal oxybutynin. Rev Urol 2006; 8(3): 93–103

    PubMed  Google Scholar 

  6. European Medicines Agency. European public assessment report (scientific discussion): Kentera [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Kentera/176804en6.pdf [Accessed 2009 Feb 25]

  7. Sand PK. Subjective measures of efficacy: quality of life, patient satisfaction and patient-oriented goals — the search for value. Eur Urol Suppl 2007; 6(5): 438–43

    Article  Google Scholar 

  8. Watson Pharmaceuticals Inc. Oxytrol (oxybutynin transdermal system) patch: US prescribing information [online]. Available from URL: http://pi.watson.com/data_stream.asp?product_group=1295&p=pi&language=E [Accessed 2009 Feb 25]

  9. European Medicines Agency. Summary of product characteristics: Kentera 3.9 mg/24 hours, transdermal patch [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Kentera/H-532-PI-en.pdf [Accessed 2009 Feb 25]

  10. Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995; 6(3): 243–62

    Article  PubMed  CAS  Google Scholar 

  11. Comer AM, Goa KL. Extended-release oxybutynin. Drugs Aging 2000 Feb; 16: 149–55

    Article  PubMed  CAS  Google Scholar 

  12. Bang LM, Easthope SE, Perry CM. Transdermal oxybutynin: for overactive bladder. Drugs Aging 2003; 20(11): 857–64

    Article  PubMed  CAS  Google Scholar 

  13. Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997 Mar; 157(3): 1093–7

    Article  PubMed  CAS  Google Scholar 

  14. Oki T, Toma-Okura A, Yamada S. Advantages for transdermal over oral oxybutynin to treat overactive bladder: muscarinic receptor binding, plasma drug concentration, and salivary secretion. J Pharmacol Exp Ther 2006 Mar; 316(3): 1137–45

    Article  PubMed  CAS  Google Scholar 

  15. Davila GW, Daugherty CA, Sanders SW. A short-term, multi-center, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001 Jul; 166(1): 140–5

    Article  PubMed  CAS  Google Scholar 

  16. Zobrist RH, Schmid B, Feick A, et al. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res 2001 Jul; 18(7): 1029–34

    Article  PubMed  CAS  Google Scholar 

  17. Zobrist RH, Quan D, Thomas HM, et al. Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. Pharm Res 2003 Jan; 20(1): 103–9

    Article  PubMed  CAS  Google Scholar 

  18. Hill LA, Caramelli KE, Thomas HM. Comparative bioavailability and metabolism of transdermal oxybutynin (OXY-TDS) applied to the buttocks and back [abstract no. 252]. Annual Meeting of the American College of Clinical Pharmacy; 2007 Oct 14–17; Denver (CO)

  19. Appell RA, Chancellor MB, Zobrist RH, et al. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 2003 Jun; 78(6): 696–702

    Article  PubMed  CAS  Google Scholar 

  20. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003; 62(2): 237–42

    Article  PubMed  Google Scholar 

  21. Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002 Aug; 168(2): 580–6

    Article  PubMed  CAS  Google Scholar 

  22. Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int 2007 Apr; 99(4): 836–44

    Article  PubMed  CAS  Google Scholar 

  23. Dmochowski RR, Sanders SW, Appell RA, et al. Bladder-health diaries: an assessment of 3-day vs 7-day entries. BJU Int 2005; 96: 1049–54

    Article  PubMed  Google Scholar 

  24. Sand PK, Goldberg RP, Dmochowski RR, et al. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol 2006 Dec; 195(6): 1730–5

    Article  PubMed  Google Scholar 

  25. Staskin DR, Rosenberg MT, Dahl NV, et al. Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. Int J Clin Pract 2008 Jan; 62(1): 27–38

    Article  PubMed  CAS  Google Scholar 

  26. Pizzi LT, Talati A, Gemmen E, et al. Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study. Pharmacoeconomics. In press

  27. Davila GW, Sand PK, Gonick CW, et al. Impact of transdermal oxybutynin on nocturia and related symptoms in overactive bladder: results from MATRIX study. Obstet Gynecol 2006 Apr; 107 Suppl.: 76

    Article  Google Scholar 

  28. Sand PK, Lucente VR, Parker RL, et al. Impact of transdermal oxybutynin on depression symptoms in patients with overactive bladder: results of the MATRIX study. Obstet Gynecol 2006 Apr; 107 Suppl.: 76

    Article  Google Scholar 

  29. Staskin DR, Nitti VW, Dmochowski RR. Quality of life following treatment with transdermal oxybutynin: the effects of prior therapy [abstract no. 84]. Neurourol Urodyn 2006 Jan 1; 25(6): 611–2

    Google Scholar 

  30. Sand PK, Dahl NV. Satisfaction with transdermal oxybutynin treatment for overactive bladder in women younger and those older than 45 years. Obstet Gynecol 2008 Apr; 111 (4 Suppl.): 111S

    Google Scholar 

  31. Hamad RA, Dmochowski RR, McIlwain M, et al. MATRIX results: does quality of life differ in overactive bladder patients older and younger than 75 years treated with transdermal oxybutynin? J Am Geriatr Soc 2006 Apr 1; 54 Suppl.: 22

    Google Scholar 

  32. Davila WG, Dahl NV. Transdermal oxybutynin treatment for overactive bladder in women receiving estrogen therapy. Obstet Gynecol 2008 Apr; 111 (4 Suppl.): 112S

    Google Scholar 

  33. Sand P, McIlwain M. Transdermal oxybutynin for overactive bladder: satisfaction and perceived effectiveness [abstract no. 89]. 38th Annual Meeting of the International Continence Society; 2008 Oct 20–24; Cairo

  34. Dmochowski RR, Nitti V, Staskin D, et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005 Sep; 23(4): 263–70

    Article  PubMed  CAS  Google Scholar 

  35. Ko Y, Malone DC, Armstrong EP. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Pharmacotherapy 2006 Dec; 26(12): 1694–702

    Article  PubMed  CAS  Google Scholar 

  36. Sverre JM, Holm LB, Kristensen FKO. A cost-minimization analysis of oxybutynin (transdermal delivery system) compared to tolterodine (tablets) in the treatment of patients with urge or mixed urinary incontinence in Sweden. Value Health 2007 Dec; 10: 315. Plus poster presented at ISPOR 10th Annual European Congress; 2007 Oct 20–23; Dublin.

Download references

Acknowledgements and Disclosures

This manuscript was reviewed by: R. Ajmera, Department of Urology, JLN Medical College and Hospital, Ajmer, India; R.R. Dmochowski, Department of Urology, Vanderbilt Continence Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Wolters Kluwer Health | Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Claudine M. Baldwin & Gillian M. Keating

  2. Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

    Claudine M. Baldwin & Gillian M. Keating

Authors
  1. Claudine M. Baldwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claudine M. Baldwin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baldwin, C.M., Keating, G.M. Transdermal Oxybutynin. Drugs 69, 327–337 (2009). https://doi.org/10.2165/00003495-200969030-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200969030-00008

Keywords

Search

Navigation